Cancer Target Discovery and Development Network (U01)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) will continue to support the program "Cancer Target Discovery and Development” (CTD^2, pronounced cee-tee-dee-squared).  CTD^2 is focused on efforts that advance cancer research by bridging the knowledge gap between the rapidly increasing volumes of new data generated by comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.

The primary purpose of the CTD^2 program is to advance our understanding of cancer etiology, mechanisms and treatment through:

  • Improving the understanding of how mutations in cancer genes affect the downstream functions (e.g., gain-of-function, loss-of-function, or neomorphic function) within the protein and cellular pathway(s);
  • Searching for new molecular targets with the goal to overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and
  • Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity.

This FOA solicits applications for research projects  advancing the goals outlined above. The proposed projects should use a combination of state-of-the-art high throughput informatic and experimental approaches to address at a minimum two of these three research areas: (1)  characterization and validation of novel cancer targets; (2) identification of molecular markers that can meaningfully predict responses or resistance to anticancer therapies; and (3) development of perturbagens that can affect the proposed targets of cancer treatment.   

Applicant organization may submit two applications, provided that each application is scientifically distinct and based on different self-standing project (although, if desired and appropriate, these two projects may be designed as a broadly-based interactive effort).


  • Duke Internal Deadline: August 10, 2016
  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): October 3, 2016

​RFA-CA-16-014 Expiration Date October 4, 2016

Agency Website



Amount Description

Budgets up to $750,000 direct costs per year may be requested.

A project period of up to 5 years may be requested if justified. Shorter project periods may also be requested commensurate with the nature of the project(s) proposed. 

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

Internal Nomination

If you are interested in applying for this opportunity, please submit a 1 to 2 page letter of intent (LOI ) describing your research proposal and a NIH style biosketch (5 page maximum, listing no more than 15 publications) to Erin Carr ( by Wednesday, August 10th. Applicants will be notified of the internal review outcome by August 26th with the full grant due to the NIH by Monday, October 3, 2016.

Internal Deadline

August 10, 2016

External Deadline

October 3, 2016